Country
Full text data for US,EP,CN
Type
Legal Validity
Legal Status
Filing Date
Publication Date
Inventor
Assignee
Click to expand
IPC(Section)
IPC(Class)
IPC(Subclass)
IPC(Group)
IPC(Subgroup)
Agent
Agency
Claims Number
Figures Number
Citation Number of Times
Assignee Number
No. Publication Number Title Publication/Patent Number Publication/Patent Number Publication Date Publication Date
Application Number Application Number Filing Date Filing Date
Inventor Inventor Assignee Assignee IPC IPC
1
US10918714B2
Human iNKT cell activation using glycolipids with altered glycosyl groups
Publication/Patent Number: US10918714B2 Publication Date: 2021-02-16 Application Number: 16/175,504 Filing Date: 2018-10-30 Inventor: Wong, Chi-huey   Yu, Alice L.   Lin, Kun-hsien   Wu, Tai-na   Assignee: ACADEMIA SINICA   IPC: A61K39/39 Abstract: Glycosphingolipids (GSLs) bearing α-glucose (α-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with α-glucose (α-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with α-galactose (α-Gal) are disclosed. GSLs bearing α-glucose (α-Glc) and derivatives of α-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with α-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with α-Glc and derivatives thereof are provided.
2
US2021070843A1
METHOD FOR HIGH-THROUGHPUT SCREENING OF NEUTRALIZING ANTIBODIES, NEUTRALIZING ANTIBODIES PRODUCED THEREFROM, AND USES THEREOF
Publication/Patent Number: US2021070843A1 Publication Date: 2021-03-11 Application Number: 16/757,460 Filing Date: 2018-10-19 Inventor: Yang, An-suei   Chen, Ing-chien   Chiu, Yi-kai   Yu, Chung-ming   Lee, Cheng-chung   Tung, Chao-ping   Tsou, Yueh-liang   Huang, Yi-jen   Lin, Chia-lung   Chen, Hong-sen   Wang, Hwei-jiung   Assignee: ACADEMIA SINICA   IPC: C07K16/10 Abstract: Disclosed herein are methods for high-throughput screening of a virus-specific neutralizing antibody. According to certain embodiments of the present disclosure, the virus is an influenza virus. Also disclosed herein are the antibodies selected by the high-throughput screening method, and the uses thereof in the prophylaxis and/or treatment of viral infection.
3
US2021030825A1
USE OF CRASSOCEPHALUM RABENS EXTRACT IN THE TREATMENT OF BREAST CANCER
Publication/Patent Number: US2021030825A1 Publication Date: 2021-02-04 Application Number: 16/963,992 Filing Date: 2018-05-29 Inventor: Shyur, Lie-fen   Apaya, Maria Karmella   Chang, Meng-ting   Assignee: ACADEMIA SINICA   IPC: A61K36/28 Abstract: A method for treating breast cancer and/or treating breast cancer metastasis in a subject in need of such treatment including administering to said subject an effective amount of Crassocephalum rabens extract and optionally a pharmaceutically acceptable carrier or excipient.
4
US10978091B2
System and methods for suppression by selecting wavelets for feature compression in distributed speech recognition
Publication/Patent Number: US10978091B2 Publication Date: 2021-04-13 Application Number: 16/205,328 Filing Date: 2018-11-30 Inventor: Tsao, Yu   Wang, Syu-siang   Assignee: ACADEMIA SINICA   IPC: G10L25/69 Abstract: A system is provided to realize suppression by selecting wavelets for feature compression in distributed speech recognition. The system comprises a first device and a second device. The first device comprising: a first network module for connecting to a network; an acoustic transducer module for recording speech and outputting frames of recorded signal; and a first processor configured for the following: extracting multiple-dimensional speech features from the frames of the recorded signal to generate multiple feature sequences; applying discrete wavelet transform (DWT) to the feature sequences to obtain a plurality of component data; and transmitting at least one of the plurality of component data via the network, wherein another one of the plurality of component data is not transmitted. The second device comprising: a second network module for connecting to the network and receiving the at least one of the plurality of component data from the first device; and a second processor configured for the following: updating the received data to generate an updated data; and applying inverse discrete wavelet transform (IDWT) to the updated data to obtain reconstructed speech data.
5
US10971677B2
Electrically controlled nanomagnet and spin orbit torque magnetic random access memory including the same
Publication/Patent Number: US10971677B2 Publication Date: 2021-04-06 Application Number: 16/709,965 Filing Date: 2019-12-11 Inventor: Lin, Hsin   Wu, Shih-yu   Hsu, Chuang-han   Assignee: ACADEMIA SINICA   IPC: H01L43/04 Abstract: An electrically controlled nanomagnet and a spin orbit torque magnetic random access memory (SOT-MRAM) including the same are provided. The electrically controlled nanomagnet includes: a first spin-Hall material layer including a first spin-Hall material; a second spin-Hall material layer including a second spin-Hall material; and a first magnetic layer disposed between the first spin-Hall material layer and the second spin-Hall material layer, wherein the first spin-Hall material and the second spin-Hall material are substantially mirror image to each other.
6
US2021113610A1
TREATMENT FOR AUTISTIC SPECTRUM DISORDER (ASD) AND RELEVANT SYMPTOMS
Publication/Patent Number: US2021113610A1 Publication Date: 2021-04-22 Application Number: 17/077,504 Filing Date: 2020-10-22 Inventor: Hsueh, Yi-ping   Huang, Tzyy-nan   Assignee: ACADEMIA SINICA   IPC: A61K33/30 Abstract: The present invention relates to a method for treating autism spectrum disorders (ASD) or ASD-like symptom, particularly by administering a zinc ion source and/or a serine component e.g. D-serine or its precursor/analogue, optionally in combination with a mixture of branched-chain amino acids (BCAAs). The present invention also relates to a combination, kit or composition for performing the method for treatment as described herein. Further described is use of a zinc ion source and/or a serine component and optional BCAAs for manufacturing a medicament for treating a symptom or disease characteristics associated with ASD or ASD-associated disorder or as a food supplement for ameliorating relevant symptoms in a subject in need thereof. The present invention further provides an animal model for autistic spectrum disorder (ASD) with deficient CTTNBP2 gene, and a method for identifying an ingredient effective in the treatment of ASD by using such animal model.
7
US10987369B2
Pdia4 protein as a target for diagnosis, monitoring and treatment of diabetes
Publication/Patent Number: US10987369B2 Publication Date: 2021-04-27 Application Number: 15/302,938 Filing Date: 2015-04-09 Inventor: Yang, Wen-chin   Chang, Lee-tian   Assignee: ACADEMIA SINICA   IPC: A61K31/7028 Abstract: A Pdia4 inhibitor for use in preventing, alleviating and/or treating diabetes and/or diabetes-related complications in a subject in need thereof is disclosed, wherein the Pdia4 inhibitor does not comprise cytopiloyene. A Pdia4 inhibitor and one other anti-diabetic agent for use in combination therapy in preventing, alleviating, treating diabetes and diabetes-related complications, and/or reversing diabetes in a subject in need thereof is also disclosed, wherein the Pdia4 inhibitors for use in combination therapy may comprise cytopiloyene. Also disclosed are methods for diagnosing, treating and monitoring diabetes, and methods of screening for a Pdia4 inhibitor and/or an anti-diabetic agent.
8
US10912832B2
Multi-drug delivery system and uses thereof
Publication/Patent Number: US10912832B2 Publication Date: 2021-02-09 Application Number: 16/697,810 Filing Date: 2019-11-27 Inventor: Hsieh, Patrick C. H.   Wu, Pei-jung   Roffler, Steve   Cheng, Bill   Assignee: ACADEMIA SINICA   IPC: A61K39/395 Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemia disease is also provided.
9
US10912777B2
Dipyridamole for use in treating SLC29A2 nuclear-expressing cancer
Publication/Patent Number: US10912777B2 Publication Date: 2021-02-09 Application Number: 16/470,952 Filing Date: 2017-12-19 Inventor: Jou, Yuh-shan   Shen, Roger   Assignee: ACADEMIA SINICA   IPC: A61K31/519 Abstract: A pharmaceutical composition comprising (i) a therapeutically effective amount of an inhibitor of the oncogene SLC29A2; and (ii) a pharmaceutically acceptable carrier, for use in suppressing proliferation, occurrence, and metastasis of cancer cells overexpressing the oncogene SLC29A2 in a cancer patient, and/or prolonging cancer patient survival. The inhibitor of the oncogene SLC29A2 may be at least one selected from the group consisting of dipyridamole, dilazep, draflzine, nitorbenzylthioinosine, and the derivatives thereof. The composition for use may further comprise sorafenib for the same use.
10
US10894037B2
Inhibitors of bacterial two component signal transduction system and uses thereof
Publication/Patent Number: US10894037B2 Publication Date: 2021-01-19 Application Number: 16/233,280 Filing Date: 2018-12-27 Inventor: Chen, Chinpan   Tseng, Tien-sheng   Tsai, Keng-chang   Assignee: ACADEMIA SINICA   IPC: A61K31/422 Abstract: Disclosed herein are novel uses of a compound of formula (I) as an inhibitor of bacterial two component signal transduction system (TCS), A-L-B-L-A  (I) wherein, A is a moiety having a negative charge; L is —(C2H5—O)n—CH2— or a moiety consists of a carbocyclyl and a heterocyclyl respectively having 5 to 10 ring atoms and coupling together, in which n is 0 or 1; and B is a 5 to 10-membered carbocyclyl or heterocyclyl. The compound of formula (I) may suppress or inhibit the growth of bacteria, including the notorious multi-drug resistant bacteria.
11
US2021071153A1
RECOMBINANT POLYNUCLEOTIDE SEQUENCE FOR PRODUCING ASTAXANTHIN AND USES THEREOF
Publication/Patent Number: US2021071153A1 Publication Date: 2021-03-11 Application Number: 17/094,623 Filing Date: 2020-11-10 Inventor: Chang, Jui-jen   Thia, Caroline   Lin, Hao-yeh   Lin, Yu-ju   Huang, Chieh-chen   Li, Wen-hsiung   Assignee: ACADEMIA SINICA   IPC: C12N9/14 Abstract: Disclosed herein are recombinant polynucleotide sequences, vectors, host cells and methods for producing astaxanthin. The recombinant polynucleotide sequence is designed to provide a higher level of astaxanthin precursors via a shorter metabolic pathway, and thereby attains higher level of end products (e.g., astaxanthin) with desired stereoisomeric form and/or esterified form.
12
US10882890B2
Bipartite molecules and uses thereof in treating diseases associated with abnormal protein aggregates
Publication/Patent Number: US10882890B2 Publication Date: 2021-01-05 Application Number: 15/328,593 Filing Date: 2015-07-24 Inventor: Tu, Benjamin Pang-hsien   Chen, Rita Py   Huang, Joseph Jen-tse   Chern, Yijuang   Jang, Yu-song   Lai, Xiang-me   Liao, Tai-yan   Kung, Te-hsien   Assignee: ACADEMIA SINICA   IPC: C07K14/47 Abstract: Bipartite molecules comprising a peptide affinity moiety and at least one charged moiety and uses thereof in reducing formation of abnormal protein aggregate and treating diseases associated with such abnormal protein aggregate, including neurodegenerative disease characterized by formation of protein aggregates.
13
US10941130B2
Molten salt system and method and apparatus of transformation for multi-carbon production by using the same
Publication/Patent Number: US10941130B2 Publication Date: 2021-03-09 Application Number: 16/362,172 Filing Date: 2019-03-22 Inventor: Chung, Po-wen   Bhaumik, Prasenjit   Chou, Hao-ju   Assignee: Academia Sinica   IPC: C07D307/46 Abstract: This invention relates to a novel molten salt system in chemical transformation of saccharides and a method as well as an apparatus for multi carbon production by the molten salt system. It is found that an eutectic molten salt composition is advantageous for multi-carbon productions through chemical transformation under mild conditions. This invention further provides a method and an apparatus for preparing 5-hydroxymethylfurfural (HMF) and HMF-derived chemicals from saccharides by the said molten salt system.
14
US10983133B2
Diagnosis and treatment of Kawasaki disease
Publication/Patent Number: US10983133B2 Publication Date: 2021-04-20 Application Number: 15/327,280 Filing Date: 2015-07-23 Inventor: Chen, Yuan-tsong   Wu, Jer-yuarn   Ko, Tai-ming   Kuo, Ho-chang   Chang, Jeng-sheng   Assignee: Academia Sinica   IPC: A61K39/395 Abstract: Described is a method of diagnosing, treating, or monitoring a treatment for Kawasaki disease in a subject. The method includes detecting the level of a biomarker in a sample obtained from the subject, the biomarker being IL-7F, sCD40L, MPIF-1, E-selectin, IP-10, or IL-33. The level is compared to a cut-off level. Also described is a kit for carrying out the method.
15
US2021088514A1
CAPTURE, PURIFICATION, AND RELEASE OF BIOLOGICAL SUBSTANCES USING A SURFACE COATING
Publication/Patent Number: US2021088514A1 Publication Date: 2021-03-25 Application Number: 16/832,396 Filing Date: 2020-03-27 Inventor: Chang, Ying-chih   Wu, Han-chung   Tseng, Po-yuan   Wu, Jen-chia   Assignee: Academia Sinica   IPC: G01N33/543 Abstract: This invention relates to a surface coating for capture circulating rare cells, comprising a nonfouling composition to prevent the binding of non-specific cells and adsorption of serum components; a bioactive composition for binding the biological substance, such as circulating tumor cells; with or without a linker composition that binds the nonfouling and bioactive compositions. The invention also provide a surface coating for capture and purification of a biological substance, comprising a releasable composition to release the non-specific cells and other serum components; a bioactive composition for binding the biological substance, such as circulating tumor cells; with or without a linker composition that binds the releasable and bioactive compositions. The present invention also discloses a novel microfluidic chip, with specific patterned microstructures to create a flow disturbance and increase the capture rate of the biological substance.
16
EP3773606A1
MIR-17~92 AS THERAPEUTIC OR DIAGNOSTIC TARGET OF MOTOR NEURON (MN) DEGENERATION DISEASES
Publication/Patent Number: EP3773606A1 Publication Date: 2021-02-17 Application Number: 19780579.9 Filing Date: 2019-04-02 Inventor: Chen, Jun-an   Peng, Kuan-chih   Tung, Ying-tsen   Assignee: Academia Sinica   IPC: A61K31/7105
17
EP3789766A1
NOVEL GLYCAN CONJUGATES AND METHODS OF USE THEREOF
Publication/Patent Number: EP3789766A1 Publication Date: 2021-03-10 Application Number: 20204837.7 Filing Date: 2015-08-21 Inventor: Wong, Chi-huey   Wu, Chung-yi   Assignee: Academia Sinica   IPC: G01N33/53 Abstract: The present disclosure is directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA3/SSEA4/GloboH associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globo-series glycosphingolipid synthesis. The present disclosure relates to methods and compositions which can modulate the globo-series glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globo-series glycosphingolipid SSEA3/SSEA4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globo-series synthetic pathway. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions.
18
US2021087239A1
PARASPECKLE COMPONENT 1 (PSPC1) PROMOTING EPITHELIAL-MESENCHYMAL TRANSITION, STEMNESS AND METASTASIS AS AN ANTI-CANCER TARGET
Publication/Patent Number: US2021087239A1 Publication Date: 2021-03-25 Application Number: 16/970,350 Filing Date: 2020-02-12 Inventor: Jou, Yuh-shan   Lang, Yaw-dong   Yeh, Hsi-wen   Assignee: Academia Sinica   IPC: C07K14/47 Abstract: An isolated nucleic acid encoding a C-terminal fragment of paraspeckle component 1 (PSPC1) is disclosed. The C-terminal fragment of the PSPC1 comprises an extension of more than 10 but no greater than 131 amino acid residues with its C-terminal amino acid identical to the C-terminus of the PSPC1 sequence SEQ ID NO: 3 and exhibits a biological activity against tumor cells. The tumor cells are associated with either PSPC1 or protein tyrosine kinase 6 (PTK6), or both. The anti-tumor activity is at least one selected from the group consisting of: (a) suppressing tumor cell growth; (b) suppressing tumor cell progression; (c) suppressing tumor cell metastasis; (d) decreasing PSPC1 expression; and (e) decreasing oncogenic PTK6 expression in cytoplasm. Also disclosed is a peptide comprising a C-terminal fragment sequence of PSPC1. A reagent kit and method for predicting tumor progression, metastasis, and prognosis in a cancer patient are also disclosed.
19
US2021113608A1
OCTASACCHARIDES AND USES THEREOF
Publication/Patent Number: US2021113608A1 Publication Date: 2021-04-22 Application Number: 16/771,643 Filing Date: 2018-12-12 Inventor: Hung, Shang-cheng   Kadomatsu, Kenji   Sakamoto, Kazuma   Ko, Yen-chun   Tsai, Cheng-fang   Fan, Chiao-yuan   Assignee: Academia Sinica   IPC: A61K31/737 Abstract: Disclosed herein is a sulfated octasacchande of formula (I), a pharmaceutically acceptable salt, solvate or ester thereof: wherein R1 is —NHAc or —NHSO3H; and R2 and R3 are independently H, or —SO3H. Also encompasses herein is a method of treating neuron injury and/or diseases associated with a autophagy flux. The method includes administering an effective amount of the sulfated octasaccharide of formula (I) to a subject in need of such treatment.
20
US10889611B2
Sialyltransferase inhibitors and uses thereof
Publication/Patent Number: US10889611B2 Publication Date: 2021-01-12 Application Number: 15/754,806 Filing Date: 2016-08-26 Inventor: Li, Wen-shan   Hung, Wen-chun   Shen, Chia-ning   Assignee: Academia Sinica   IPC: A61P35/00 Abstract: Disclosed herein are novel sialyltransferase inhibitors, and compositions and methods for treating diseases and/or conditions associated with the activation of sialyltransferase, such as a cancer, an immune disease or an inflammatory disease.